Additional Information
Book Details
Abstract
This issue of Surgical Oncology Clinics of North America, Guest Edited by John M. Kane III, MD, is devoted to Sarcomas. Articles in this issue include: Prognostic Factors and Staging for Soft Tissue Sarcomas; Margin Status and Local Recurrence: Correlation or Causation?; Systemic Chemotherapy in the Adjuvant and Clinical Metastatic Setting; Pulmonary Metastasectomy; Regional Therapy for Advanced Extremity Sarcomas; Current Approaches to Retroperitoneal Sarcomas; Updates on the Management of Gastrointestinal Stromal Tumors (GIST); Soft Tissue Sarcoma: Immunologic Implications; Atypical Lipomatous Tumor/Well Differentiated Liposarcoma: What is it?; Modern Surgical Therapy: Limb Salvage and the Role of Amputation; Adjuvant Radiation Therapy: and Preoperative, Postoperative, or Not at All.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Soft Tissue Sarcomas | i | ||
| Copyright Page\r | ii | ||
| Contributors | iii | ||
| Table of Contents | vii | ||
| Foreword | xiii | ||
| Preface | xv | ||
| Chapter 1. Prognostic Factorsand Staging for Soft Tissue Sarcomas: An Update | 187 | ||
| KEYWORDS | 187 | ||
| INCIDENCE AND EPIDEMIOLOGY | 187 | ||
| GENETICS | 189 | ||
| CLINICAL PRESENTATION AND STAGING | 190 | ||
| DIAGNOSTIC BIOPSY | 191 | ||
| STS GRADING SYSTEMS | 191 | ||
| STS STAGING SYSTEMS | 194 | ||
| ADDITIONAL PROGNOSTIC FACTORS | 195 | ||
| THE FUTURE/CONCLUSIONS | 196 | ||
| REFERENCES | 197 | ||
| Chapter 2. Modern Surgical Therapy: Limb Salvage and the Roleof Amputation for Extremity Soft-Tissue Sarcomas | 201 | ||
| RISK FACTORS FOR RECURRENCE AND DEATH | 202 | ||
| LIMB-SALVAGE SURGERY | 202 | ||
| RECONSTRUCTION | 203 | ||
| RADIATION THERAPY | 204 | ||
| PREOPERATIVE VERSUS POSTOPERATIVE RADIATION THERAPY | 205 | ||
| BRACHYTHERAPY | 206 | ||
| ISOLATED LIMB PERFUSION | 207 | ||
| ISOLATED LIMB INFUSION | 208 | ||
| CHEMOTHERAPY | 208 | ||
| REGIONAL HYPERTHERMIA | 209 | ||
| AMPUTATION | 210 | ||
| SUMMARY | 210 | ||
| REFERENCES | 211 | ||
| Chapter 3. Radiation Therapy: Neoadjuvant, Adjuvant,or Not at All | 215 | ||
| OVERVIEW | 215 | ||
| EXTREMITY AND TRUNCAL STS | 216 | ||
| RETROPERITONEAL SARCOMAS | 233 | ||
| REFERENCES | 235 | ||
| Chapter 4. AdjuvantChemotherapy fo Soft Tissue Sarcomas | 243 | ||
| ADJUVANT SYSTEMIC CHEMOTHERAPY FOR STS | 244 | ||
| NEOADJUVANT CHEMOTHERAPY FOR STS | 248 | ||
| HISTOLOGY-SPECIFIC ADJUVANT CHEMOTHERAPY TRIALS | 249 | ||
| THE CONTROVERSY AND SUMMARY | 251 | ||
| REFERENCES | 252 | ||
| Chapter 5. Margin Status, Local Recurrence, and Survival: Correlationor Causation? | 255 | ||
| WHAT IS THE APPROPRIATE STS RESECTION MARGIN? | 256 | ||
| PATHOLOGIC ASSESSMENT OF THE STS RESECTION MARGIN | 256 | ||
| MARGIN STATUS AND LR | 257 | ||
| POSITIVE MARGINS, LR, AND SURVIVAL | 260 | ||
| MANAGEMENT OF THE POSITIVE RESECTION MARGIN | 262 | ||
| ACKNOWLEDGMENTS | 265 | ||
| REFERENCES | 265 | ||
| Chapter 6. Pulmonary Metastasectomy for Soft Tissue Sarcoma | 269 | ||
| IMAGING EVALUATION | 270 | ||
| FACTORS AFFECTING PATIENT SELECTION FOR PM | 271 | ||
| SURGICAL APPROACH TO PM | 272 | ||
| EXTENT OF RESECTION | 275 | ||
| RECURRENCE AND REPEATED PM | 276 | ||
| LONG-TERM SURVIVAL FOLLOWING PM | 277 | ||
| ADJUVANT THERAPY AFTER PM | 277 | ||
| NONSURGICAL ABLATIVE THERAPY FOR PULMONARY METASTASES | 279 | ||
| SUMMARY | 280 | ||
| REFERENCES | 280 | ||
| Chapter 7. Isolated Regional Therapy for Advanced Extremity Soft Tissue Sarcomas | 287 | ||
| INDICATIONS FOR REGIONAL THERAPY | 288 | ||
| TECHNIQUE OF HILP | 288 | ||
| TECHNIQUE OF ILI | 289 | ||
| TOXICITY | 290 | ||
| OUTCOME AFTER HILP FOR EXTREMITY STS | 292 | ||
| OUTCOME AFTER ILI FOR EXTREMITY STS | 292 | ||
| LIMB PRESERVATION WITH HILP | 293 | ||
| LIMB PRESERVATION WITH ILI | 294 | ||
| PALLIATIVE ISOLATED REGIONAL THERAPY | 294 | ||
| LOCOREGIONAL RECURRENCE AFTER ISOLATED REGIONAL THERAPY | 296 | ||
| SUMMARY | 296 | ||
| REFERENCES | 296 | ||
| Chapter 8. Updates on the Management of Gastrointestinal Stromal Tumors | 301 | ||
| EPIDEMIOLOGY | 301 | ||
| CLINICAL PRESENTATION AND DIAGNOSIS | 301 | ||
| PATHOLOGIC FINDINGS | 302 | ||
| TREATMENT | 304 | ||
| PEDIATRIC GIST | 310 | ||
| FAMILIAL GIST | 310 | ||
| FUTURE STRATEGIES | 310 | ||
| SUMMARY | 311 | ||
| REFERENCES | 311 | ||
| Chapter 9. Improving Outcomes for Retroperitoneal Sarcomas: A Workin Progress | 317 | ||
| RPS CLINICAL OUTCOME MEASURES | 318 | ||
| PROGNOSTIC VARIABLES FOR RPS OUTCOME | 319 | ||
| IMPROVING RPS OUTCOMES | 322 | ||
| SUMMARY | 328 | ||
| REFERENCES | 329 | ||
| Chapter 10. Atypical LipomatousTumor/Well-Differentiated Liposarcoma: What Is It? | 333 | ||
| PATHOLOGIC CLASSIFICATION OF ADIPOCYTIC TUMORS | 333 | ||
| CLINICAL EVALUATION OF WDLPS | 335 | ||
| SURGICAL RESECTION | 335 | ||
| THE ROLE OF RADIATION THERAPY | 336 | ||
| RECURRENCE | 336 | ||
| SUMMARY | 337 | ||
| REFERENCES | 338 | ||
| Chapter 11. Sarcomas and the Immune System: Implications for Therapeutic Strategies | 341 | ||
| HISTORICAL PERSPECTIVE | 342 | ||
| CLINICAL DATA FOR SARCOMA IMMUNOTHERAPY | 347 | ||
| FUTURE DIRECTIONS | 350 | ||
| SUMMARY | 351 | ||
| REFERENCES | 351 | ||
| Index | 357 |